XML 67 R49.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaboration and License Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2022 USD ($) | Mar. 31, 2020 USD ($) | Jun. 30, 2019 USD ($) | May 31, 2018 USD ($) | Jul. 31, 2017 USD ($) | Apr. 30, 2016 USD ($) AccountingUnit Agreement Target | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Mar. 31, 2017 Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 11,147 | $ 12,853 | $ 9,040 | $ 21,893 | $ 33,040 | $ 53,163 | $ 37,312 |  |
Type of Revenue [Extensible List] |  |  |  |  |  |  |  |  |  |  |  | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |  |
Deferred revenue | $ 301,326 |  |  |  |  |  |  |  |  |  |  | $ 301,326 | $ 284,760 | $ 318,707 |
AbbVie Ireland Unlimited Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  | $ 26,600 |  | $ 9,900 |  |  | $ 2,972 | $ 6,775 | $ 1,751 | $ 8,526 | $ 11,498 |  |  |  |
AbbVie Ireland Unlimited Company | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  | 14,000 |  |  |  |  |  |  |  |  |
Total transaction price |  |  |  |  |  | 39,800 |  |  |  |  |  |  |  |  |
Estimated sublicense fees |  |  |  |  |  | $ 4,200 |  |  |  |  |  |  |  |  |
Number of accounting units | AccountingUnit |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Second Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in estimated collaboration amount | 4,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of collaboration agreements | Agreement |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Percentage of net profits or net losses related to development and commercialization costs |  |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | CD71 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | $ 20,000 |  |  |  |  |  | 100,000 |  |  |
Milestone payments received |  | 40,000 |  | 21,000 | $ 14,000 |  |  |  |  |  |  | 100,000 |  |  |
Total transaction price |  |  |  |  |  | 29,800 |  |  |  |  |  |  |  |  |
Milestone payment received |  | $ 40,000 |  | 21,000 |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 4,000 |  |  |  |  |  |  |  |  |  |  | 4,000 | 16,100 |  |
AbbVie Ireland Unlimited Company | CD71 Agreement | Transferred over Time |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Type of Revenue [Extensible List] |  | us-gaap:LicenseAndServiceMember |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | CD71 Agreement | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  |
Estimated sublicense fees |  |  |  |  |  | 4,200 |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  | $ 14,000 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | CD71 Agreement | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Profit split on U.S. sales |  |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | CD71 Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments receivable upon achieving development, regulatory and commercial milestones |  |  |  |  |  | $ 470,000 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Seattle Genetics Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fees paid |  |  |  | $ 4,000 | $ 1,000 |  |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Seattle Genetics Agreement | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fees paid |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Discovery Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |
Number of targets selected | Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Total transaction price |  |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |
Deferred revenue | $ 0 |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 6,500 |  |
AbbVie Ireland Unlimited Company | Discovery Agreement | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received |  |  | $ 10,000 |  |  | $ 10,000 |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |
Estimated research service period |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |
AbbVie Ireland Unlimited Company | Discovery Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of targets | Target |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |

X
- Definition Aggregate collaboration transaction amount. + References No definition available. + Details
Name: | ctmx_AggregateCollaborationTransactionAmount
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Change in estimated collaboration transaction amount. + References No definition available. + Details
Name: | ctmx_ChangeInEstimatedCollaborationTransactionAmount
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payments receivable profit split on sales. + References No definition available. + Details
Name: | ctmx_ContingentPaymentsReceivableProfitSplitOnSales
Namespace Prefix: | ctmx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent payments receivable upon achieving development, regulatory and commercial milestones. + References No definition available. + Details
Name: | ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Estimated research service period. + References No definition available. + Details
Name: | ctmx_EstimatedResearchServicePeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Estimated sublicense fees. + References No definition available. + Details
Name: | ctmx_EstimatedSublicenseFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | ctmx_MilestonePaymentReceived
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments receivable. + References No definition available. + Details
Name: | ctmx_MilestonePaymentsReceivable
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments received from revenue recognized during period. + References No definition available. + Details
Name: | ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of accounting units. + References No definition available. + Details
Name: | ctmx_NumberOfAccountingUnits
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of collaboration agreements. + References No definition available. + Details
Name: | ctmx_NumberOfCollaborationAgreements
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of targets. + References No definition available. + Details
Name: | ctmx_NumberOfTargets
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of targets selected. + References No definition available. + Details
Name: | ctmx_NumberOfTargetsSelected
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments of sublicense fees. + References No definition available. + Details
Name: | ctmx_PaymentsOfSublicenseFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of net Income or net losses related to development and commercialization costs. + References No definition available. + Details
Name: | ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts
Namespace Prefix: | ctmx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources. + References No definition available. + Details
Name: | us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_SecondTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_SeattleGeneticsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |